MSCLF 0.40 Satellos Bioscience Inc.
| Range: | 0.22-0.6183 | Vol Avg: | 11660 | Last Div: | 0 | Changes: | 0.11 |
| Beta: | 1 | Cap: | 0.07B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Fri Aug 03 2012 | Empoloyees: | 3 | ||
| CUSIP: | CIK: | 0001421642 | ISIN: | CA80401L3083 | Country: | CA | |
| CEO: | Mr. Francis Gleeson B.B.A. M.B.A | Website: | https://satellos.com | ||||
Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics to treat degenerative muscle diseases. Its lead program focuses on the development of oral therapeutic drug to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
Stock Details
Positive 0.36
Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSC...
businesswire.com·Wed Sep 18 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow